Adjunctive Periodontal Treatment With Coenzyme Q10 in Association With Probiotics for Pregnant Women
Launched by UNIVERSITY OF PAVIA · Mar 6, 2024
Trial Information
Current as of August 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The aim of the study is to assess if probiotic supplementation can be effective in reducing periodontal clinical parameters in a 6-month study on pregnant patients. Patients' enrollment will be conducted according to inclusion criteria.
At the first visit, periodontal parameters will be recorded: Plaque Index (PI), recession (R) Bleeding on Probing (BoP), modified Marginal Gingival Index (mMGI), Papillary Marginal Gingival (PMGI), Plaque Control Record ( PCR %), Approximal Plaque Index (API), Clinical Attachment loss (CAL) and Probing Pocket Depth (PPD).
Professional debridement will be c...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • women at the 4th month of pregnancy
- Exclusion Criteria:
- • presence of cardiac pacemaker
- • neurological and psychiatric diseases
- • patients taking bisphosphonates during the previous 12 months from the beginning of the study
- • patients undergoing anticancer therapy.
- • patients with poor compliance.
About University Of Pavia
The University of Pavia, a prestigious institution renowned for its commitment to academic excellence and research innovation, serves as a prominent clinical trial sponsor. With a strong emphasis on advancing medical knowledge and improving patient care, the university leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical research. Collaborating with leading healthcare professionals and institutions, the University of Pavia is dedicated to exploring novel therapeutic approaches and fostering the translation of scientific discoveries into clinical practice, ultimately aiming to enhance health outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pavia, Lombardy, Italy
Patients applied
Trial Officials
Andrea Scribante, DDS, PhD
Principal Investigator
University of Pavia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported